Yüklüyor......
Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re‐treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re‐treatment was effective in patients with chronic plaque psoriasis. OBJECTIVES: To describe the effects of tofacitin...
Kaydedildi:
| Yayımlandı: | J Eur Acad Dermatol Venereol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5297866/ https://ncbi.nlm.nih.gov/pubmed/27600367 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.13808 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|